Philips teams up with Visiopharm to boost breast cancer diagnosis objectivity through computational pathology

Philips teams up with Visiopharm to boost breast cancer diagnosis objectivity through computational pathology
• Breast cancer patients in Europe are set to benefit from more objective diagnosis • Philips’ digital pathology offering to be complemented with Visiopharm breast cancer panel algorithms Amsterdam, the Netherlands – Royal Philips (NYSE: PHG,...
Read more

Part 1: An Update on the FDA’s Regulation of Digital Pathology

Part 1: An Update on the FDA’s Regulation of Digital Pathology
FDA representative Tremel Faison made it clear last week, during the Regulatory Panel at the Pathology Visions conference, that digital pathology systems will be classified as a class III medical device, requiring manufacturers seeking...
Read more